Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

camonagrel

Known as: 5-(2-imidazol-1-ylethoxy)-1-indancarboxylic acid 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Camonagrel is a novel selective thromboxane synthetase inhibitor. The aim of this study was to determine its main pharmacokinetic… Expand
  • figure 1
  • figure 2
  • table I
  • table III
2003
2003
The aim of this study was to compare the effects of a new thromboxane synthase inhibitor, camonagrel, on platelet aggregation and… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
2002
2002
Recent evidence suggests that hypoxic pulmonary vasoconstriction (HPV) is mediated by hypoxia-induced closure of voltage-gated… Expand
  • figure 1
  • figure 2
1999
1999
We characterised early circulatory and respiratory responses to lipopolysaccharide from E. coli (LPS, serotype 0127:B8) in the… Expand
1999
1999
The mechanism of early pulmonary and systemic haemodynamic response to intravenous infusion of LPS from Escherichia coli was… Expand
1998
1998
Platelet hyperactivity accompanied by an increased synthesis of thromboxane and/or a decreased prostacyclin production are… Expand
  • table 1
  • figure 4
  • figure 5
1998
1998
We present for the first time direct continuous assay of NO concentration (porphyrinic sensor) in the lung parenchyma of Sprague… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
1996
1996
Six hours after administration of E. Coli endotoxin (LPS) into rats (10 mg kg-1, i.p.) a significant (P < 0.001) decline in the… Expand
1996
1996
Here we report that streptokinase is responsible for forming thrombi both in vitro on blood-superfused endothelial cells of… Expand
1995
1995
So far pharmacological consequences of inhibition of thromboxane A2 (TXA2) synthase by imidazole derivatives (e.g., camonagrel or… Expand